GRAIL
History
| Year | Detail |
|---|---|
| 2016 | Grail company was founded and announced to focus on early cancer detection. |
| 2017 | The company received $ 1 billion in Series B funding after receiving $100 million in a Series A funding round. |
| 2020 | The company announces completion of series D funding of $390M. The funding provides resources to the company to develop and authorize blood-based cancer screening tests. |
| The company partners with the UK's National Health Service to make available the Galleri, a multi-cancer early-detection blood test. | |
| 2021 | Illumina acquired Grail in a $8 billion deal. Illumina holds the Grail as a separate company after its acquisition during the regulatory review by the European Commission's. |
| 2022 | The company partnered with AstraZeneca to develop companion diagnostic tests to enable the treatment of early-stage cancer. |
| 2023 | The company introduced a methylation-based solution to accelerate cancer research in the post-diagnosis setting. |
BCC Research Beacon 